In the last trading session, 1.2 million Kymera Therapeutics Inc (NASDAQ:KYMR) shares changed hands as the company’s beta touched 2.22. With the company’s per share price at $46.50 changed hands at $1.95 or 4.38% during last session, the market valuation stood at $2.87B. KYMR’s last price was a discount, traded about -4.73% off its 52-week high of $48.70. The share price had its 52-week low at $9.60, which suggests the last value was 79.35% up since then. When we look at Kymera Therapeutics Inc’s average trading volume, we note the 10-day average is 0.41 million shares, with the 3-month average coming to 591.97K.
Analysts gave the Kymera Therapeutics Inc (KYMR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.71. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended KYMR as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Kymera Therapeutics Inc’s EPS for the current quarter is expected to be -0.84.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Kymera Therapeutics Inc (NASDAQ:KYMR) trade information
Instantly KYMR was in green as seen at the end of in last trading. With action 8.14%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 82.64%, with the 5-day performance at 8.14% in the green. However, in the 30-day time frame, Kymera Therapeutics Inc (NASDAQ:KYMR) is 9.49% up. Looking at the short shares, we see there were 9.85 million shares sold at short interest cover period of 13.56 days.
The consensus price target for the stock as assigned by Wall Street analysts is 52, meaning bulls need an upside of 10.58% from its current market value. According to analyst projections, KYMR’s forecast low is 31 with 80 as the target high. To hit the forecast high, the stock’s price needs a -72.04% plunge from its current level, while the stock would need to tank 33.33% for it to hit the projected low.
Kymera Therapeutics Inc (KYMR) estimates and forecasts
Data shows that the Kymera Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 22.27% over the past 6 months, a -13.89% in annual growth rate that is considerably lower than the industry average of 18.30%. Year-over-year growth is forecast to reach -27.30% down from the last financial year.
Consensus estimates given by 15 financial analysts project the company’s revenue in the current quarter to hit an average of 10.59M. 14 analysts are of the opinion that Kymera Therapeutics Inc’s revenue for the current quarter will be 10.99M. The company’s revenue for the corresponding quarters a year ago was 4.73M and 47.88M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 124.00%. The estimates for the next quarter sales put growth at -77.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -39.18%. The 2024 estimates are for Kymera Therapeutics Inc earnings to decrease by -16.28%, but the outlook for the next 5-year period is at 1.90% per year.
KYMR Dividends
Kymera Therapeutics Inc is expected to release its next quarterly earnings report in September.
Kymera Therapeutics Inc (NASDAQ:KYMR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.34% of Kymera Therapeutics Inc shares while 110.66% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 112.16%. There are 110.66% institutions holding the Kymera Therapeutics Inc stock share, with PRICE T ROWE ASSOCIATES INC /MD/ the top institutional holder. As of 2024-03-31, the company held 10.8489% of the shares, roughly 6.33 million KYMR shares worth $254.55 million.
BAKER BROS. ADVISORS LP holds the second largest percentage of outstanding shares, with 10.2731% or 6.0 million shares worth $241.04 million as of 2024-03-31.
